The Pharmacology of Adrenaline: Mechanisms, Uses, and Clinical Pearls

Adrenaline, also known as epinephrine, is the quintessential emergency medication that can reverse anaphylaxis, maintain cardiac output in cardiac arrest, and support blood pressure during severe shock. In 2022, the American Heart Association reported that epinephrine was administered in 12.5% of out‑of‑hospital cardiac arrest cases, underscoring its critical role in acute care. Understanding its pharmacology is essential for clinicians, pharmacists, and students alike, as mis‑dosing or delayed administration can be the difference between life and death.

Introduction and Background

Adrenaline was first isolated in 1895 by Jokichi Takamine, who named it after the adrenal glands where it is produced. It belongs to the catecholamine class, structurally similar to dopamine and norepinephrine, and acts as a non‑selective agonist at alpha‑ and beta‑adrenergic receptors. Clinically, it is available as an injectable solution for emergency use and as a nebulized inhaler for asthma (adrenaline sulfate 0.5 mg/mL). The drug’s unique ability to stimulate both vasoconstrictive and inotropic pathways makes it indispensable in critical care.

From a pathophysiological standpoint, adrenaline’s effects are mediated by the sympathetic nervous system’s “fight‑or‑flight” response, increasing heart rate, myocardial contractility, bronchodilation, and glycogenolysis. In anaphylaxis, the massive release of histamine and leukotrienes leads to vasodilation and bronchoconstriction; adrenaline counteracts these effects by stimulating beta‑2 receptors in the airways and alpha‑1 receptors in the vasculature. In cardiac arrest, it enhances coronary perfusion pressure and improves myocardial contractility, thereby increasing the likelihood of return of spontaneous circulation (ROSC).

Mechanism of Action

Alpha‑1 Adrenergic Receptor Activation

Adrenaline binds to alpha‑1 receptors on vascular smooth muscle, activating the Gq protein. This leads to phospholipase C stimulation, IP3 production, and intracellular calcium release, which causes vasoconstriction. The resulting increase in systemic vascular resistance (SVR) elevates arterial blood pressure, crucial in treating hypotension and shock.

Beta‑1 Adrenergic Receptor Activation

Beta‑1 receptors in the heart are coupled to Gs proteins, stimulating adenylyl cyclase and increasing cyclic AMP (cAMP). Elevated cAMP activates protein kinase A, which phosphorylates L-type calcium channels and phospholamban, enhancing calcium influx and sarcoplasmic reticulum calcium release. The net effect is increased heart rate (chronotropy), contractility (inotropy), and conduction velocity (dromotropy).

Beta‑2 Adrenergic Receptor Activation

In the bronchial smooth muscle, beta‑2 receptors also couple to Gs proteins, raising cAMP and leading to relaxation of smooth muscle fibers. This bronchodilatory action is the basis for adrenaline’s use in acute asthma and anaphylactic bronchospasm. Additionally, beta‑2 stimulation in skeletal muscle vasculature causes vasodilation, improving peripheral perfusion.

Other Molecular Effects

Adrenaline’s catechol structure enables it to inhibit phosphodiesterase (PDE) activity, prolonging cAMP action. It also stimulates glycogen phosphorylase, promoting glycogenolysis and gluconeogenesis, providing a rapid glucose source during stress. In the kidneys, beta‑1 activation increases renin release, contributing to the renin‑angiotensin‑aldosterone system (RAAS) activation during hypotension.

Clinical Pharmacology

Pharmacokinetics and pharmacodynamics of adrenaline vary with route of administration. The following table summarizes key parameters for the most common formulations.

Pharmacodynamics: The dose‑response relationship is steep for alpha‑1 mediated vasoconstriction and beta‑1 mediated cardiac effects. Therapeutic doses for anaphylaxis range from 0.3 mg IV to 0.5 mg IM, with repeat dosing every 5–15 minutes if symptoms persist. In cardiac arrest, the standard dose is 1 mg IV/IO every 3–5 minutes until ROSC.

Therapeutic Applications

• Anaphylaxis – 0.3–0.5 mg IV or IM, repeat as needed; 1 mg IV in severe cases.
• – 1 mg IV/IO every 3–5 minutes; can be given as a continuous infusion if prolonged arrest.
• – 0.5 mg nebulized; repeat every 20 minutes as needed.
• – 0.5–1 mg IV, titrated to maintain MAP >65 mmHg.
• – Low‑dose continuous infusion (0.01–0.1 µg/kg/min) in ICU settings.

Off‑label uses: Adrenaline is sometimes employed in refractory vasoplegic syndrome post‑cardiac surgery, as an adjunct in severe sepsis with vasodilatory shock, and in certain cases of severe bradycardia unresponsive to atropine.

Special populations:
• Pediatric: Dose calculated by weight (0.01–0.03 mg/kg IM/IV). Neonates may receive 0.01 mg/kg IV for cardiac arrest.
• Geriatric: No dose adjustment necessary, but monitor for arrhythmias due to increased cardiac sensitivity.
• Renal/hepatic impairment: No dose adjustment; however, monitor for accumulation of metabolites if severe impairment.
• Pregnancy: Category C; use only if benefits outweigh risks; administer the lowest effective dose.

Adverse Effects and Safety

Common side effects include tachycardia (40–60% incidence), palpitations (25–35%), hypertension (15–20%), headache, anxiety, tremor, and diaphoresis. Less common but serious adverse events are arrhythmias (ventricular tachycardia, ventricular fibrillation), myocardial ischemia, and pulmonary edema.

Black box warnings: Due to the risk of life‑threatening arrhythmias, especially in patients with pre‑existing cardiac disease or electrolyte abnormalities.

Drug interactions: Adrenaline’s effects can be potentiated or diminished by concurrent medications. The following table lists major interactions.

Monitoring parameters: Continuous ECG, blood pressure, heart rate, serum electrolytes (particularly potassium), and cardiac biomarkers in high‑risk patients. Contraindications include uncontrolled hypertension, known hypersensitivity to catecholamines, and severe cardiac arrhythmias.

Clinical Pearls for Practice

• PEARL 1: In anaphylaxis, always administer adrenaline IM first, then IV if symptoms persist; never delay the first dose.
• PEARL 2: For cardiac arrest, use 1 mg IV/IO every 3–5 minutes; avoid continuous infusion unless arrest >30 minutes.
• PEARL 3: In pediatric patients, calculate dose by weight (0.01–0.03 mg/kg) and avoid exceeding 0.5 mg total.
• PEARL 4: Adrenaline’s alpha‑1 effects can mask underlying hypovolemia; always assess volume status and consider fluid resuscitation concurrently.
• PEARL 5: Use a mnemonic “SAD” (Shock, Anaphylaxis, Deteriorating cardiac arrest) to remember scenarios where adrenaline is first‑line.
• PEARL 6: In patients on beta‑blockers, be prepared to repeat doses or consider alternative vasopressors if response is blunted.
• PEARL 7: Adrenaline’s short half‑life (2–3 minutes IV) necessitates rapid administration and repeat dosing; do not wait for signs of improvement before re‑dosing.

Comparison Table

Exam‑Focused Review

Common exam question stems often revolve around the appropriate dosing, route of administration, and contraindications of adrenaline. Students frequently confuse the dosing of adrenaline for anaphylaxis (0.3–0.5 mg IM) with the dose for cardiac arrest (1 mg IV/IO). Another frequent point of confusion is the difference between alpha‑1 mediated vasoconstriction and beta‑1 mediated inotropy—both are important but serve distinct clinical purposes.

Key facts for NAPLEX, USMLE, and clinical rotations:
• Adrenaline’s half‑life is only 2–3 minutes IV; continuous infusion is rarely needed.
• In anaphylaxis, adrenaline is the first‑line therapy; antihistamines and steroids are adjuncts.
• In cardiac arrest, adrenaline improves coronary perfusion pressure but may reduce cerebral perfusion if over‑used; thus, limit to 10–12 doses.
• Beta‑blockers can blunt adrenaline’s effects; consider alternative vasopressors if response is inadequate.
• Adrenaline’s side effect profile includes tachyarrhythmias; monitor ECG in patients with pre‑existing arrhythmias.

Key Takeaways

1. Adrenaline is a non‑selective catecholamine acting on alpha‑1, beta‑1, and beta‑2 receptors.
2. Its rapid onset and short half‑life make it ideal for emergency situations like anaphylaxis and cardiac arrest.
3. IV dosing for cardiac arrest is 1 mg every 3–5 minutes; for anaphylaxis, 0.3–0.5 mg IM is first‑line.
4. Adrenaline’s alpha‑1 effects raise SVR, while beta‑1 increases cardiac output; beta‑2 causes bronchodilation.
5. Common adverse effects include tachycardia, hypertension, and arrhythmias; black box warning for arrhythmias exists.
6. Drug interactions with beta‑blockers, MAO inhibitors, and COMT inhibitors can alter efficacy and safety.
7. Special populations: pediatric dosing is weight‑based; geriatric patients require ECG monitoring; pregnancy requires lowest effective dose.
8. Clinical pearls: IM first in anaphylaxis, repeat dosing if needed, monitor ECG in high‑risk patients, and be cautious in patients on beta‑blockers.
9. Adrenaline is often confused with noradrenaline; remember adrenaline is first‑line for anaphylaxis and cardiac arrest, while noradrenaline is preferred for septic shock.
10. Exam preparation: focus on dose, route, timing, and contraindications; practice differentiating similar vasopressors.

Always remember: In emergencies, time is muscle and brain—administer adrenaline promptly, monitor closely, and adjust based on response.